ABBV vs VRTX
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. VRTX: Vertex is a leader in biotechnology primarily recognized for its dominance in cystic fibrosis therapy and its emerging pipeline of gene-editing treatments and non-opioid pain relief.
Side-by-side fundamentals
| Metric | ABBV | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $264.52 | $547.59 | |
| Market cap as of 2026-08-24 | $467.4B | $138.8B | |
| P/E as of 2026-08-24 | 74.32 | 31.86 | VRTX lower |
| PEG as of 2026-08-24 | 6.59 | 2.28 | VRTX lower |
| Net margin as of 2026-08-24 | +9.8% | +35.0% | VRTX higher |
| Gross margin as of 2026-08-24 | +72.8% | +86.0% | VRTX higher |
| Operating margin as of 2026-08-24 | +26.2% | +38.0% | VRTX higher |
| ROE as of 2026-08-24 | +95.6% | +23.3% | ABBV higher |
| ROA as of 2026-08-24 | +4.7% | +16.9% | VRTX higher |
| Debt / equity as of 2026-08-24 | 49.22 | 0.00 | VRTX lower |
| Revenue growth (YoY) as of 2026-08-24 | +10.4% | +10.2% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +10.4% | VRTX higher |
| Dividend yield as of 2026-08-24 | +4.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.27 | 0.48 | |
| 1-year return as of 2026-08-24 close | +25.6% | +38.6% | VRTX higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.